Table_1_OLFML2B Is a Robust Prognostic Biomarker in Bladder Cancer Through Genome-Wide Screening: A Study Based on Seven Cohorts.xlsx

BackgroundBladder cancer lacks useful and robust prognostic markers to stratify patients at risk. Our study is to identify a robust prognostic marker for bladder cancer.MethodsThe transcriptome and clinical data of bladder cancer were downloaded from multiple databases. We searched for genes with robust prognosis by Kaplan-Meier analysis of the whole genome. CIBERSORT and TIMER algorithm was used to calculate the degree of immune cell infiltration.ResultsWe identified OLFML2B as a robust prognostic marker for bladder cancer in five cohorts. Kaplan-Meier analysis showed that patients with a high level of OLFML2B expression had a poor prognosis. The expression of OLFML2B increased with the increase of stage and grade. We found that patients with high expression of OLFML2B still had a poor prognosis in two small bladder cancer cohorts. OLFML2B also has the prognostic ability in ten other tumors, and the prognosis is poor in high expression. The correlation analysis between OLFML2B and immune cells showed that it was positively correlated with the degree of macrophage infiltration and highly co-expressed with tumor-associated macrophage markers. Finally, the Wound-healing assay and Colony formation assay results showed that the migration and proliferation ability of bladder cancer cell lines decreased after the knockdown of OLFML2B.ConclusionsIn summary, OLFML2B is a robust risk prognostic marker, and it can help patients with bladder cancer improve individualized treatment.

背景：膀胱癌缺乏有效的预后标志物以对高危患者进行分层。本研究旨在鉴定一种对膀胱癌具有稳健预后的标志物。方法：我们从多个数据库下载了膀胱癌的转录组和临床数据。通过全基因组Kaplan-Meier分析搜索具有稳健预后的基因。使用CIBERSORT和TIMER算法计算免疫细胞浸润程度。结果：我们在五个队列中鉴定了OLFML2B作为膀胱癌的稳健预后标志物。Kaplan-Meier分析显示，高水平OLFML2B表达的患者的预后较差。OLFML2B的表达随疾病分期和分级程度的增加而升高。我们在两个小膀胱癌队列中发现，高表达OLFML2B的患者预后仍然较差。OLFML2B在十种其他肿瘤中也具有预后能力，且高表达时预后不良。OLFML2B与免疫细胞的关联分析显示，它与巨噬细胞浸润程度呈正相关，并与肿瘤相关巨噬细胞标志物高度共表达。最终，伤口愈合实验和集落形成实验结果表明，敲低OLFML2B后，膀胱癌细胞系的迁移和增殖能力下降。结论：总之，OLFML2B是一种稳健的风险预后标志物，它有助于膀胱癌患者实现个体化治疗。